Abstract |
1,4,7,10-tetraazacyclododecane-N,N',N",N'''-tetraacetic acid ( DOTA)- lanreotide is a universal somatostatin (SST) receptor subtype ligand that binds to a large variety of human tumors. We report the case of a patient with metastatic gastrinoma who was treated with 90Y-DOTA-lanreotide. Before treatment, dosimetry with 111In-DOTA-lanreotide (150 MBq, 10 nmol) indicated a dose of 5.8 mGy/MBq for the recurrent abdominal gastrinoma, and a mean dose of approximately 1.0 mGy/MBq for liver metastases (i.e., 56 and approximately 10 mGy/MBq for 90Y- DOTA- lanreotide, respectively). After four infusions of 90Y-DOTA-lanreotide (each 1 GBq, approximately 30 nmol) over a 6-mo period, the 111In-DOTA-lanreotide scintigraphy of the liver had returned to a nearly normal condition and a remarkably decreased uptake by the recurrent gastrinoma was calculated (approximately 5 mGy/MBq for 90Y- DOTA- lanreotide). The imaging results were well-correlated with a 25% regression of the liver metastases as indicated by CT. Blood, urine and whole-body clearances of 111In-DOTA-lanreotide and 90Y-DOTA-lanreotide were very similar. The DOTA- lanreotide promises to be useful for functional tumor diagnosis (111In-DOTA-lanreotide) and receptor-mediated tumor radiotherapy (90Y-DOTA-lanreotide).
|
Authors | M Leimer, A Kurtaran, P Smith-Jones, M Raderer, E Havlik, P Angelberger, F Vorbeck, B Niederle, C Herold, I Virgolini |
Journal | Journal of nuclear medicine : official publication, Society of Nuclear Medicine
(J Nucl Med)
Vol. 39
Issue 12
Pg. 2090-4
(Dec 1998)
ISSN: 0161-5505 [Print] United States |
PMID | 9867148
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Heterocyclic Compounds
- Peptides, Cyclic
- Radiopharmaceuticals
- Receptors, Somatostatin
- indium 111-DOTA-lanreotide
- yttrium 90-DOTA-lanreotide
|
Topics |
- Gastrinoma
(diagnostic imaging, pathology, radiotherapy, secondary)
- Heterocyclic Compounds
(pharmacokinetics, therapeutic use)
- Humans
- Liver Neoplasms
(diagnostic imaging, radiotherapy, secondary)
- Lymph Node Excision
- Male
- Metabolic Clearance Rate
- Middle Aged
- Pancreatic Neoplasms
(pathology, radiotherapy, surgery)
- Peptides, Cyclic
(pharmacokinetics, therapeutic use)
- Radiopharmaceuticals
(pharmacokinetics, therapeutic use)
- Receptors, Somatostatin
(agonists)
- Recurrence
- Tomography, Emission-Computed, Single-Photon
- Tomography, X-Ray Computed
|